Hepatic encephalopathy (HE) is associated with substantial healthcare utilization (e.g. hospitalizations), which rifaximin has been shown to reduce (e.g. reduction in risk of overt HE recurrence, reduction in overt HE-related hospitalizations).

The economic burden of HE on healthcare systems, including annual hospitalizations for patients with overt HE, may be mitigated by rifaximin.

The cost savings and clinical benefits of rifaximin in patients with cirrhosis have the potential to benefit healthcare decision making regarding management of HE.